Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700)
- 6 July 2020
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 98 (11), 763-770
- https://doi.org/10.1159/000507733
Abstract
Objectives: Induction chemotherapy followed by cetuximab and RT (IBRT) (Arm A) was compared to cisplatin/RT (CRT) (Arm B) in a randomized phase III study. Patients and Methods: Naïve patients with stage III-IVa, histologically proven locally advanced head and neck cancer (LASCCHN) were eligible. Arm A (IBRT): 3 TPF induction followed by cetuximab-RT (equivalent daily dose 2 Gy up to 70 Gy); Arm B: 3 cisplatin concurrent with the same RT scheduling. Due to slow accrual and incomplete data collection a futility analysis was performed. Results: 236/282 patients were evaluable. Therefore, no formal analyses can be made between the two arms. OS was 45.2/53.6 months in Arm A/B. Complete responses were achieved in 64% of patients in both arms. Neutropenia and skin toxicity were significantly worse in Arm A and body weight loss was significantly worse in Arm B. Compliance with the planned drug administration was higher in Arm B (p = 0.0008). Conclusion: The study suggests that IBRT and CRT have similar efficacy, activity and toxicity.Keywords
This publication has 13 references indexed in Scilit:
- Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized TrialJournal of Clinical Oncology, 2018
- Patient choice for high‐volume center radiation impacts head and neck cancer outcomeCancer Medicine, 2018
- Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckFrontiers in Oncology, 2017
- Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck CancerJournal of Clinical Oncology, 2014
- Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trialThe Lancet Oncology, 2013
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck CancerNew England Journal of Medicine, 2007
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2006
- An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck CancerJournal of Clinical Oncology, 2003
- Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual dataThe Lancet, 2000